# A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Immunogenicity of APG777 in Adults With Asthma

> **NCT06920901** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Apogee Therapeutics, Inc.** · enrollment: 31 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** APG777
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06920901
- **Lead sponsor:** Apogee Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-03-27
- **Primary completion:** 2026-09
- **Final completion:** 2027-03
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2026-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06920901

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06920901, "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Immunogenicity of APG777 in Adults With Asthma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06920901. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*